Morgan Stanley Trevi Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,024,011 shares of TRVI stock, worth $10.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,024,011

Previous 494,567 107.05%

Holding current value

$10.9 Million

Previous $3.11 Million 80.1%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$5.28 - $7.06 $2.8 Million - $3.74 Million	529,444 Added 107.05%	1,024,011 $5.6 Million
Q1 2025 May 15, 2025	BUY	$3.66 - $6.81 $1.11 Million - $2.07 Million	303,698 Added 159.11%	494,567 $3.11 Million
Q4 2024 Feb 14, 2025	SELL	$2.53 - $4.5 $19,255 - $34,249	-7,611 Reduced 3.83%	190,869 $813,000
Q3 2024 May 14, 2025	BUY	$2.58 - $3.51 $282,507 - $384,341	109,499 Added 123.06%	198,480 $662,000
Q3 2024 Nov 14, 2024	BUY	$2.58 - $3.51 $282,507 - $384,341	109,499 Added 123.06%	198,480 $662,000
Q2 2024 May 14, 2025	SELL	$2.44 - $3.36 $248,606 - $342,343	-101,888 Reduced 53.38%	88,981 $265,000
Q2 2024 Oct 17, 2024	BUY	$2.44 - $3.36 $50,639 - $69,733	20,754 Added 30.42%	88,981 $265,000
Q2 2024 Aug 14, 2024	BUY	$2.44 - $3.36 $50,639 - $69,733	20,754 Added 30.42%	88,981 $265,000
Q1 2024 Oct 17, 2024	SELL	$1.3 - $3.7 $26,980 - $76,789	-20,754 Reduced 23.32%	68,227 $235,000
Q1 2024 Aug 16, 2024	SELL	$1.3 - $3.7 $105,008 - $298,871	-80,776 Reduced 54.21%	68,227 $235,000
Q1 2024 May 15, 2024	SELL	$1.3 - $3.7 $105,008 - $298,871	-80,776 Reduced 54.21%	68,227 $235,000
Q4 2023 Aug 16, 2024	BUY	$1.06 - $2.05 $63,623 - $123,045	60,022 Added 67.45%	149,003 $199,000
Q4 2023 Feb 13, 2024	BUY	$1.06 - $2.05 $121,146 - $234,292	114,289 Added 329.23%	149,003 $199,000
Q3 2023 Nov 15, 2023	SELL	$2.11 - $2.47 $6,492 - $7,600	-3,077 Reduced 8.14%	34,714 $75,000
Q2 2023 Aug 14, 2023	BUY	$1.8 - $3.44 $67,332 - $128,680	37,407 Added 9741.41%	37,791 $90,000
Q1 2023 May 15, 2023	SELL	$1.69 - $2.97 $92 - $163	-55 Reduced 12.53%	384 $0
Q4 2022 Feb 14, 2023	SELL	$1.61 - $2.42 $689,025 - $1.04 Million	-427,966 Reduced 99.9%	439 $0
Q3 2022 Nov 14, 2022	BUY	$1.54 - $4.28 $659,743 - $1.83 Million	428,405 New	428,405 $660,000
Q2 2022 Aug 15, 2022	SELL	$1.8 - $3.39 $1,060 - $1,996	-589 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$0.46 - $2.48 $270 - $1,460	589 New	589 $1,000
Q1 2022 May 13, 2022	BUY	$0.46 - $2.48 $270 - $1,460	589 New	589 $1,000

Others Institutions Holding TRVI

# of Institutions

164

Shares Held

110M

Call Options Held

1.07M

Put Options Held

425K

View Full List

About Trevi Therapeutics, Inc.

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $618M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

More about TRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account